Public Defence: Oksana Svärd - Molecular Biology
M.Sc. Oksana Svärd at Norwegian centre for molecular medicine will be defending the thesis “Chromatin dynamics during human hematopoietic development” for the degree of PhD (Philosophiae Doctor).
Photo: John Hughes Photography 2013
Trial Lecture – time and place
See Trial Lecture.
- First opponent: Researcher Lorena Arranz, Department of Medical Biology, Faculty of Health Sciences, UiT – The Arctic University of Norway
- Second opponent: Researcher Gregor Gilfillan, Centre Department of Medical Genetics, Oslo University Hospital
- Third member and chair of the evaluation committee: Professor Hilde Loge Nilsen, Faculty of Medicine, University of Oslo
Chair of the Defence
Assistant Director Hartmut Luecke, Faculty of Medicine, University of Oslo
Head of Group Judith Staerk, Faculty of Medicine, University of Oslo
The transition from one cell type to another requires a global change in gene expression, which is regulated through genetic and epigenetic mechanisms. A major mechanism of gene regulation is the interaction of genomic regions with the nuclear lamina. These regions have been identified in numerous cell types and chromatin bound to the nuclear lamina is generally associated with transcriptional repression, however there is still large gaps in the understanding of the underlying mechanisms. Using the hematopoietic system we have investigated how chromatin interacts with two major components of the nuclear lamina: Lamin B1 and lamin B receptor (LBR). We have created genome wide maps of these interactions by chromatin immunoprecipitation (ChIP) in progenitor cells as well as mature blood cells, allowing us to characterize chromatin regions associated with the nuclear lamina common to all analysed cell types as well as cell type specific ones. We show that interactions are lineage and differentiation specific, with differing border demarcation and enrichment in epigenetic marks. Our work provides an important resource for studying chromatin organization by LaminB1 and LBR in healthy and malignat blood development.
Contact the research support staff.